Literature DB >> 598930

Studies on serum and cerebrospinal fluid levels of cephacetrile in neonates.

A Windorfer, U Gasteiger.   

Abstract

The serum half-life of cephacetrile and its penetration from the serum into the cerebrospinal fluid (CSF) was determined in 33 premature and full-term neonates. On an average the serum half-life was 3.6 hours in children with a birth weight above 1,500 g; in children with a birth weight below 1,500 g it was 5.1 hours. The penetration volume of cephacetrile into CSF was higher and the rate of penetration faster in neonates with meningeal infections than in those without. The highest CSF concentrations were reached 2-4 hours after drug application (2.6-25.8 mcg/ml in infants with bacterial meningitis and 1.8-15.2 mcg/ml in infants without).

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 598930     DOI: 10.1007/bf01640789

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  12 in total

1.  The evaluation of renal function in infancy and childhood.

Authors:  W B WEIL
Journal:  Am J Med Sci       Date:  1955-06       Impact factor: 2.378

2.  [Various aspects of the pharmacokinetics of Celospor with special reference to its affinity to cerebrospinal fluid].

Authors:  H G Meyer-Brunot; C Schenk; K Schmid; P Spring; W Theobald; J Wagner
Journal:  Wien Med Wochenschr Suppl       Date:  1975

3.  Pharmacokinetics of a new cephalosporin, cephacetrile, in patients with normal and impaired renal function.

Authors:  S R Westenfelder; K G Naber; P O Madsen
Journal:  Infection       Date:  1973       Impact factor: 3.553

4.  [Cephacetrile (C 36278-Ba), a new antibiotic of the cephalosporin group. Pharmacokinetics and clinical investigation].

Authors:  P N Maurice; W Riess; A Welke; K Amson
Journal:  Arzneimittelforschung       Date:  1974-09

5.  Serum half-lives and elimination rates of a new semi-synthetic cephalosporin, cephacetrile, in nephrectomized patients and in patients with impaired or normal renal function.

Authors:  F Reutter; N P Maurice
Journal:  Arzneimittelforschung       Date:  1974-09

6.  Development of meningitis during cephalothin therapy.

Authors:  R J Mangi; R S Kundargi; R Quintiliani; V T Andriole
Journal:  Ann Intern Med       Date:  1973-03       Impact factor: 25.391

7.  Penetration of cephalothin into the spinal fluid.

Authors:  N J Vianna; D Kaye
Journal:  Am J Med Sci       Date:  1967-08       Impact factor: 2.378

8.  Antimicrobial studies in vitro with cephacetrile, a new cephalosporin derivative.

Authors:  F Knüsel; E A Konopka; J Gelzer; A Rosselet
Journal:  Arzneimittelforschung       Date:  1974-09

9.  Rapid microassay of gentamicin, kanamycin, neomycin, streptomycin, and vancomycin in serum or plasma.

Authors:  L D Sabath; J I Casey; P A Ruch; L L Stumpf; M Finland
Journal:  J Lab Clin Med       Date:  1971-09

10.  [Blood distribution, renal and biliary excretion of a new caphalosporin, cephacetrile (Ciba 36278 Ba)].

Authors:  J M Brogard; F Kuntzmann; J Lavillaureix
Journal:  Schweiz Med Wochenschr       Date:  1973-01-20
View more
  3 in total

1.  Clinical isolates of Canada albicans.

Authors:  R J Holt
Journal:  Infection       Date:  1979       Impact factor: 3.553

2.  Lack of penetration of cephacetril into the cerebro-spinal fluid of patients without meningitis.

Authors:  H Friedrich; K Pelz; G Hänsel-Friedrich
Journal:  Infection       Date:  1979       Impact factor: 3.553

Review 3.  The cephalosporins: activity and clinical use.

Authors:  A J Weinstein
Journal:  Drugs       Date:  1980-08       Impact factor: 9.546

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.